(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 70 Publications

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUPSZm1EOjVyL{WwNE8yODByIH7N MUGyOE81QC95MjDo NULFWY57TE2VTx?= NEPsW4NqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz M4PHTFI3PzB5OEix
BCPAP M3v2[WNmdGxiVnnhZoltcXS7IFHzd4F6 NX;0e|Z1OjVyL{WwNE8yODByIH7N NXzITohROjRxNEivO|IhcA>? MYLEUXNQ NH;peXpqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MXuyOlcxPzh6MR?=
K1  MnfmR4VtdCCFeXPs[UBCe3OjeR?= NFzs[VEzPTBxNUCwM|ExODBibl2= NYL2[3c4PzJiaB?= M3nySmROW09? MWThdpJme3S|IHPlcIwh[3mlbHWgZZQhTzBxR{GgdIhie2V? NHPhNYIzPjdyN{i4NS=>
BCPAP M3rhcWNmdGxiQ4njcIUhSXO|YYm= M2fLflI2OC93MECvNVAxOCCwTR?= MV:3NkBp NWLXNY0xTE2VTx?= MVXhdpJme3S|IHPlcIwh[3mlbHWgZZQhTzBxR{GgdIhie2V? M332e|I3PzB5OEix
Hep3B M17tUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXwcoY4OC1zMDFOwG0> MWC1JIQ> MULEUXNQ M3vrT2lEPTB;MD6wPEDPxE1? NUTubmpEOjZ3N{WxOlc>
HCCLM3 MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfvbHpPOC1zMDFOwG0> NX;5XnYxPSCm NYPGc4UyTE2VTx?= M4fqemlEPTB;MD6xOEDPxE1? NWfJXGpoOjZ3N{WxOlc>
HuH7 NHPhe4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn70NE0yOCEQvF2= NEHzSZc2KGR? NHXObIZFVVOR MWrJR|UxRTBwMkGg{txO MmHFNlY2PzVzNke=
HepG2 M2rU[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXqwMVExKM7:TR?= MYG1JIQ> M3XpVWROW09? MkTVTWM2OD1yLkO0JO69VQ>? MkPPNlY2PzVzNke=
SMMC7721 NHTtTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfjNE0yOCEQvF2= MlGzOUBl MWDEUXNQ NGHhOlBKSzVyPUCuOFEh|ryP MVmyOlU4PTF4Nx?=
BEL7402 MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TUWlAuOTBizszN MXy1JIQ> MUXEUXNQ MYjJR|UxRTBwNEeg{txO NIruRWMzPjV5NUG2Oy=>
MHCC97H M3TKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\sT5pHOC1zMDFOwG0> NV7aVIlWPSCm MYHEUXNQ NYT2ZVU{UUN3ME2wMlQyKM7:TR?= MX:yOlU4PTF4Nx?=
Hep3B M1LXWmNmdGxiQ4njcIUhSXO|YYm= NH7IVIsxNjFxMD61M|IvPSEQvF2= NGLid2w1QCCq M4X4cGROW09? MXHs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kBJS0NiY3XscJMhcW5ic4XiMWcyKHCqYYPlxsA> MVOyOlU4PTF4Nx?=
HCCLM3 NE\hbo1E\WyuIFP5Z4xmKEG|c3H5 NIO3PZQxNjFxMD61M|IvPSEQvF2= MW[0PEBp NFLMcpVFVVOR MojXcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhUEOFIHPlcIx{KGmwIIP1Zk1IOSCyaHHz[eKh M{j6WFI3PTd3MU[3
Hep3B MlnmRZBweHSxc3nzJGF{e2G7 MorCNE4yNzBwNT:yMlUh|ryP Ml;HOFghcA>? MUPEUXNQ NXrSS21z[WO2aY\heIV{KGOjc4Dhd4UuOyCjbnSgZ4F{eGG|ZT25JIV5eHKnc4Ppc44h[W6mIHnu[JVk\WRiUFHSVEBkdGWjdnHn[UBieyC5ZXzsJIF{KGO7dH;jbJJwdWViYzDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bTDmdo9uKG2rdH;jbI9v\HKrYR?= NWHjZ3h[OjZ3N{WxOlc>
HCCLM3 M{TFXmFxd3C2b4Ppd{BCe3OjeR?= MYqwMlEwOC53L{KuOUDPxE1? NVzqbGMzPDhiaB?= NX3rTlMxTE2VTx?= NF7WdJJi[3SrdnH0[ZMh[2G|cHHz[U0{KGGwZDDjZZNx[XOnLUmg[ZhxemW|c3nvckBidmRiaX7keYNm\CCSQWLQJINt\WG4YXflJIF{KHenbHygZZMh[3m2b3Podo9u\SClIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOvIH\yc40hdWm2b3Poc45lemmj NW\aTWdCOjZ3N{WxOlc>
A549 NEnRfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmn4NE4yNTFyIN88US=> M2r5N|czKGh? NWTxUY5xcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MUmyOlQyPTJ{NR?=
H157 NUPTN4ozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[wMlEuOTBizszN MV63NkBp MWXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MkjnNlY1OTV{MkW=
H1299 MmLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLwfno1OC5zLUGwJO69VQ>? M1\3bVczKGh? NX3p[o9IcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MkfUNlY1OTV{MkW=
A549 M33HSGZ2dmO2aX;uJGF{e2G7 MoTmNU8zNjVxNTFOwG0> M4G5UVEzKGh? Mnn1xsB4\WGtbImg[IVkemWjc3XkJGJkdC1{IHzleoVtew>? NHfBSogzPjRzNUKyOS=>
H1299 MYrGeY5kfGmxbjDBd5NigQ>? M33IblEwOi53L{Wg{txO MYCxNkBp M4jkeuKhf2Wja3z5JIRm[3KnYYPl[EBD[2xvMjDs[ZZmdHN? M{\mOFI3PDF3MkK1
H157 NWfWeodwTnWwY4Tpc44hSXO|YYm= NHrFTWsyNzJwNT:1JO69VQ>? M37zXlEzKGh? NILlUpNl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= MVeyOlQyPTJ{NR?=
H1299 MnPpSpVv[3Srb36gRZN{[Xl? NWTTcWppOS9{LkWvOUDPxE1? NUmzcmUzOTJiaB?= MlzU[IVkemWjc3XkJGRTPCCneIDy[ZN{cW:w Mn\uNlY1OTV{MkW=
C8161 NGrGSHBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NF73[HExNTJizszN MkHDOEBl MoPCSG1UVw>? M1jpR4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFXpT4MzPjN7N{KyNy=>
Mel285 NGi0d|BE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWqye3ZyOC1{IN88US=> MV[0JIQ> NEG0PFZFVVOR MmnB[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MX:yOlM6PzJ{Mx?=
Mel290 NILt[WdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1;u[VAuOiEQvF2= M{nE[|Qh\A>? MlzvSG1UVw>? NVrC[3RC\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M2XrOFI3Ozl5MkKz
92.1 NHjLR45E\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3;Fe|AuOiEQvF2= MonrOEBl NVXrdnJWTE2VTx?= NILtVIJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NE[yXHozPjN7N{KyNy=>
Omm1.3 NGHVdItE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXuwZpFQOC1{IN88US=> NHSxcXk1KGR? M1izcGROW09? M2XqfoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXf3dVY{OjZ|OUeyNlM>
Mel202 NWDOXlFmS2WubDDWbYFjcWyrdImgRZN{[Xl? NHXpU5YxNTJizszN MVu0JIQ> NYTzUXF4TE2VTx?= NHfFWI1l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NXTMTIpKOjZ|OUeyNlM>
Mel270 MWrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUTjWHU2OC1{IN88US=> MoDLOEBl M1mzfWROW09? NETuSXpl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NYDOcVVKOjZ|OUeyNlM>
Omm1 NXLLWFFUS2WubDDWbYFjcWyrdImgRZN{[Xl? MYewMVIh|ryP NV3kdXVwPCCm MVrEUXNQ NXjaeXN[\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MViyOlM6PzJ{Mx?=
92.1 MULBdI9xfG:|aYOgRZN{[Xl? M1XUW|UxOCCwTR?= MYi0PEBp Mn;uSG1UVw>? NHXEV3ZqdmS3Y3XzJIFxd3C2b4Ppdy=> MUeyOlM6PzJ{Mx?=
Omm1.3 NHzj[GtCeG:ydH;zbZMhSXO|YYm= M1L6fVUxOCCwTR?= NHG1Wpk1QCCq NY\WTmxVTE2VTx?= NWnwNYJEcW6mdXPld{BieG:ydH;zbZM> M1HCNVI3Ozl5MkKz
92.1 NFzWV2NE\WyuIFP5Z4xmKEG|c3H5 M2LhZlUxOCCwTR?= Mmf5NlQwPDhxN{KgbC=> M2fvXmROW09? MkHsbY5lfWOnczD0bIUh[2WubDDhZ4N2dXWuYYTpc44h[XRic4XiMWcyyqB? MVmyOlM6PzJ{Mx?=
Omm1.3 NVvMTHI4S2WubDDDfYNt\SCDc4PhfS=> MUO1NFAhdk1? NFH6SVUzPC92OD:3NkBp M331WWROW09? NFXKXnBqdmS3Y3XzJJRp\SClZXzsJIFk[3WvdXzheIlwdiCjdDDzeYIuTzIEoB?= NYLLVGpWOjZ|OUeyNlM>
A549 MYTGeY5kfGmxbjDBd5NigQ>? Ml3FNVAxNzRyMD:xNFAxKG6P M4eybFI1KGh? MlrYeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? NFq1enAzPjJzMkG5PS=>
MCF-7 M2DEdmZ2dmO2aX;uJGF{e2G7 M4j6SVExOC92MECvNVAxOCCwTR?= NIraUnkzPCCq NGq5cmx2eHKnZ4XsZZRmeyCjbnSgZYN1cX[jdHXzJHNKWlRz M1\IXlI3OjF{MUm5
HEK293 NX\ZTpNwTnWwY4Tpc44hSXO|YYm= MXSxNFAwPDByL{GwNFAhdk1? NXTsS5JlOjRiaB?= MlPZeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? MkjsNlYzOTJzOUm=
858 M3TsT2NmdGxiVnnhZoltcXS7IFHzd4F6 NVy0cWxZOC1zIN88US=> NVXnbY01PSCm MVTEUXNQ MkPv[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MoHZNlYzODZ|M{O=
DDR2L63V MojVR4VtdCCYaXHibYxqfHliQYPzZZk> Mn7aNE0yKM7:TR?= NHvRUGo2KGR? M1Tse2ROW09? NHyy[ZBl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MVeyOlIxPjN|Mx?=
BE(2)-C NFzjfopE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUixJO69VQ>? M2[4RlEuPCCm NVXGZ2c3\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? M1HzS|I3ODZ5NE[0
IMR-32 MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUexJO69VQ>? NE\SWGgyNTRiZB?= NV\EW|Bv\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? MlXNNlYxPjd2NkS=
JF MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4HQV|Eh|ryP M{jnTlEuPCCm NYOySZZK\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? NVj0Rox2OjZyNke0OlQ>
BE(2)-M17 MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mmm0NUDPxE1? M1y0VVEuPCCm NWPY[4du\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? NFn5[mszPjB4N{S2OC=>
SK-N-SH M2G4UmNmdGxiVnnhZoltcXS7IFHzd4F6 MXKxJO69VQ>? NWTvdm1ROS12IHS= M3vRUoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NGD4SWczPjB4N{S2OC=>
SK-N-DZ  M37ENmNmdGxiVnnhZoltcXS7IFHzd4F6 NGnJUFIyKM7:TR?= MVqxMVQh\A>? NEHEU2Fl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NEGzS|MzPjB4N{S2OC=>
HMC-1.1  NIHwN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVO1MVUxODBibl2= MVm0PEBp MUXEUXNQ Mm\SbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MoTRNlYxPTV|MEO=
HMC-1.2 M3vMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\VWWc2NTVyMECgcm0> MYm0PEBp NGrhOWJFVVOR Mn\wbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MUiyOlA2PTNyMx?=
ROSA KIT WT  MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{mw[|UuPTByMDDuUS=> M4rTZlQ5KGh? NWPNfIJKTE2VTx?= MVnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mn\oNlYxPTV|MEO=
ROSA KIT D816V MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXRbIVlPS13MECwJI5O NWLBSVJ[PDhiaB?= MWXEUXNQ NIS2T41qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MX:yOlA2PTNyMx?=
HMC-1.1  NFnYV2tCeG:ydH;zbZMhSXO|YYm= M2XPOVIxOC13MECwJI5O NH30OpA1QCCq NH;ZeHJFVVOR NGLScXJqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MWqyOlA2PTNyMx?=
HMC-1.2 M2roO2Fxd3C2b4Ppd{BCe3OjeR?= Mn\1NlAxNTVyMECgcm0> MVG0PEBp M2fIfGROW09? MkjIbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWDzeFM3OjZyNUWzNFM>
ROSA KIT WT  NHnI[oRCeG:ydH;zbZMhSXO|YYm= M{nSPFIxOC13MECwJI5O MYm0PEBp NY\4U5RbTE2VTx?= Ml\NbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NF3qUJUzPjB3NUOwNy=>
ROSA KIT D816V NWfqRppYSXCxcITvd4l{KEG|c3H5 M3q4[lIxOC13MECwJI5O NEPLOlY1QCCq M3ezSWROW09? M3vxO4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MY[yOlA2PTNyMx?=
494H MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVO3NkBp M3vrbmROW09? M4rEOWlEPTB;MD6xNlLDuTBwMEC0JO69VQ>? NHTCPWczPTl2NEW2Oi=>
493H NXLVdphOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7rW|Q4OiCq MXjEUXNQ M1fYPGlEPTB;MD6wOFfDuTBwMEC5JO69VQ>? MUGyOVk1PDV4Nh?=
716H M33lTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfKO|IhcA>? NIH0W4RFVVOR NVLTUnNQUUN3ME2wMlIyOsLzMD6wN|Qh|ryP NHXqcZkzPTl2NEW2Oi=>
148I MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnQOYdIPzJiaB?= M{TPcmROW09? NHfoVIRKSzVyPUCuNlg1yrFyLkCzOUDPxE1? NGf6bokzPTl2NEW2Oi=>
98Sc NVS2O4lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rHSVczKGh? NF7XT|lFVVOR NIO0T3lKSzVyPUCuNVE2yrFyLkCwOEDPxE1? M4XifFI2QTR2NU[2
89R M{\6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofrO|IhcA>? M4PaUmROW09? MkfxTWM2OD1yLkGyOuKyOC5yMEOg{txO M3PCPVI2QTR2NU[2
494L NGHVZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13yb|czKGh? NYCxZ5htTE2VTx?= NYj2bZVlUUN3ME2wMlMyP8LzMD6wNVIh|ryP MVOyOVk1PDV4Nh?=
493L M3nofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPVdI9xPzJiaB?= MXjEUXNQ NVu2fJhtUUN3ME2wMlA2OMLzMD6wNVEh|ryP NGjtTWwzPTl2NEW2Oi=>
148L M2TFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zCelczKGh? M13FbmROW09? MoPyTWM2OD1yLkG0OuKyOC5yMUeg{txO MmDUNlU6PDR3Nk[=
98L MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33CelczKGh? MmTPSG1UVw>? Ml7RTWM2OD1yLkOwPeKyOC5yMkmg{txO M33vWVI2QTR2NU[2
OS17 NEHrc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{n3TlczKGh? MY\EUXNQ NVP6ZmVDUUN3ME2wMlA4QcLzMD6wNFMh|ryP NFfhS5kzPTl2NEW2Oi=>
OS9 NXfSR5dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3CO|IhcA>? MUTEUXNQ MXLJR|UxRTBwNEC2xtExNjB{ODFOwG0> NULGfGZlOjV7NES1OlY>
MG63 NULQd2I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXNO|IhcA>? MYHEUXNQ MVrJR|UxRTBwMUG0xtExNjB{NTFOwG0> NYDqXnp7OjV7NES1OlY>
SAOS2 MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LXbVczKGh? NHPWT4FFVVOR M3H3UGlEPTB;MD6yNVfDuTBwMECzJO69VQ>? MWiyOVk1PDV4Nh?=
U2OS NF\vVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mle0O|IhcA>? NY\UOI5JTE2VTx?= M4nPOWlEPTB;MD6xPVjDuTBwMEC4JO69VQ>? NIOxcnkzPTl2NEW2Oi=>
SJSA-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDDWmVoPzJiaB?= NInwR2JFVVOR Ml;3TWM2OD1yLkGwNOKyOC5yMUCg{txO M{e5R|I2QTR2NU[2
494H M2HoS2Fxd3C2b4Ppd{BCe3OjeR?= MXWwMlI2NzBwNT:xMlAh|ryP NUPnPGxMOjRiaB?= NVvYU|diTE2VTx?= MVLpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> NX\qOmtmOjV7NES1OlY>
148I Mlz0RZBweHSxc3nzJGF{e2G7 NYXYZZl5OC5{NT:wMlUwOS5yIN88US=> MVGyOEBp NFHnU|RFVVOR M1\3OIlv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>? NEL3UGozPTl2NEW2Oi=>
OS17 MWPBdI9xfG:|aYOgRZN{[Xl? MkfCNE4zPS9yLkWvNU4xKM7:TR?= M4LBW|I1KGh? NGrMco5FVVOR MYHpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> MYSyOVk1PDV4Nh?=
494H NYe4VW1rSXCxcITvd4l{KEG|c3H5 M{nKOFHjiIoQvF2= NFXBXHk1QCCq MoT1SG1UVw>? NV;OXHlScW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 NYD4ZpJiOjV7NES1OlY>
148I NXv1SJo3SXCxcITvd4l{KEG|c3H5 MUmx5qCK|ryP M2XOWVQ5KGh? NU\pdotwTE2VTx?= MnrMbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 MnTVNlU6PDR3Nk[=
OS17 MnzRRZBweHSxc3nzJGF{e2G7 MXSx5qCK|ryP MmC0OFghcA>? NHjvfVhFVVOR MlXqbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 NUP4R2lGOjV7NES1OlY>
MOLM13 MmXURZBweHSxc3nzJGF{e2G7 M37SeFI2OCCwTR?= NVr4S4FxPDhiaB?= MUjEUXNQ NIn4PZVqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicYXpfoFzfGmwaXK= M3\VZ|I2ODV|OEK1
MV4-11  NH\Z[m1CeG:ydH;zbZMhSXO|YYm= MlPyNlUxKG6P MUW0PEBp Mo[0SG1UVw>? M3XUd4lv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCzdXn6ZZJ1cW6rYh?= NGnKT24zPTB3M{iyOS=>
MOLM13 M165emZ2dmO2aX;uJGF{e2G7 MlzrNlUxKG6P NVTHT|FPOjRiaB?= MYDEUXNQ NIDtVnZmdmijbnPld{ByfWm8YYL0bY5q[i2rbnT1Z4VlKG2xcnWgdFIyNCCESV2sJIFv\CClbHXheoVlKFCDUmC= MnrVNlUxPTN6MkW=
MV4-11  M1\6SGZ2dmO2aX;uJGF{e2G7 MljkNlUxKG6P MYCyOEBp NEP6eVhFVVOR NXzXWVRw\W6qYX7j[ZMheXWrenHyeIlvcWJvaX7keYNm\CCvb4LlJJAzOSxiQlnNMEBidmRiY3zlZZZm\CCSQWLQ NUPZdZkxOjVyNUO4NlU>
MOLM13 M{fyXGFxd3C2b4Ppd{BCe3OjeR?= NXnUNG9POjVyIH7N MX20PEBp M4LKU2ROW09? M2nzXolv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCyb37heIlvcWJ? Mnu3NlUxPTN6MkW=
MV4-11  NWDB[pN2SXCxcITvd4l{KEG|c3H5 MWKyOVAhdk1? NVKw[5h4PDhiaB?= NILDVZRFVVOR Mm\UbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHCxbnH0bY5q[g>? M1LYVVI2ODV|OEK1
Hela NWjze|RjS2WubDDWbYFjcWyrdImgRZN{[Xl? MnLNNE02ODBibl2= NXG5XVZMPzJiaB?= MonvSG1UVw>? NFTXU|Nl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MVWyOVAxQTJ7NR?=
HBL-1 NHS5ZoZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mle0NE02ODBibl2= NYns[VJxPzJiaB?= MYPEUXNQ MmfJ[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3Tlb|I2ODB7Mkm1
HLY-1 NYTaSFdoS2WubDDWbYFjcWyrdImgRZN{[Xl? M4XGSlAuPTByIH7N Ml3JO|IhcA>? NF3yWZVFVVOR NITBN5Nl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGLibnEzPTByOUK5OS=>
OCI-Ly3 Mm\DR4VtdCCYaXHibYxqfHliQYPzZZk> NGD1NGwxNTVyMDDuUS=> M{D6Z|czKGh? M2TzU2ROW09? Ml7X[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUm1XoFuOjVyMEmyPVU>
OCI-Ly10 MlfVR4VtdCCYaXHibYxqfHliQYPzZZk> NELq[|AxNTVyMDDuUS=> MlXMO|IhcA>? M13VfmROW09? Mnv0[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnHTNlUxODl{OUW=
SU-DHL-4 NIe2THpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYCwMVUxOCCwTR?= M{XQN|czKGh? MVvEUXNQ Mmfs[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYKyOVAxQTJ7NR?=
SU-DHL-5 NWj6W4R2S2WubDDWbYFjcWyrdImgRZN{[Xl? NGnmNFUxNTVyMDDuUS=> MV[3NkBp NET2b25FVVOR M4X2ZoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MmfLNlUxODl{OUW=
SU-DHL-6 MkDuR4VtdCCYaXHibYxqfHliQYPzZZk> MmXzNE02ODBibl2= M4W0SVczKGh? MX7EUXNQ NFu2OItl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NIHyXokzPTByOUK5OS=>
SU-DHL-10 M2jSTmNmdGxiVnnhZoltcXS7IFHzd4F6 MXywMVUxOCCwTR?= MV63NkBp M1OxcGROW09? Ml;m[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NF60RVUzPTByOUK5OS=>
RC-K8 MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NG[2eY4xNTVyMDDuUS=> M3L0R|czKGh? NWLIbHhjTE2VTx?= M3;mRYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFOxcHkzPTByOUK5OS=>
OCI-Ly8 M12wb2NmdGxiVnnhZoltcXS7IFHzd4F6 MnrMNE02ODBibl2= NU[3T5B{PzJiaB?= MVjEUXNQ MoDL[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MkHoNlUxODl{OUW=
OCL-Ly18 MnTVR4VtdCCYaXHibYxqfHliQYPzZZk> M1\zTVAuPTByIH7N NUGzbJFTPzJiaB?= M2PNeGROW09? Moj3[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NFvXe3AzPTByOUK5OS=>
OCI-Ly3 NYXSR|k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrHNVczNzJ3MD:1NFAhdk1? M2fXdFIwPyCm M1;DfGROW09? M4jZdolv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= NYSxWIh{OjVyMEmyPVU>
OCI-Ly8 M{DscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLZNVczNzJ3MD:1NFAhdk1? MUOyM|ch\A>? Mom3SG1UVw>? MVXpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi MXyyOVAxQTJ7NR?=
SU-DHL-4 NHPvRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDHUGEyPzJxMkWwM|UxOCCwTR?= NFnpXVczNzdiZB?= NWHQe25XTE2VTx?= NEXmT2xqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg NF7uNFczPTByOUK5OS=>
SU-DHL-10 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUixO|IwOjVyL{WwNEBvVQ>? NISzVnMzNzdiZB?= NVrHb2V3TE2VTx?= NVTEfYV[cW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> NFPL[I0zPTByOUK5OS=>
OCI-Ly3 MWDBdI9xfG:|aYOgRZN{[Xl? NH\oXIkyPzJxMkWwJI5O NH61Tmw4\A>? NG\YcnpFVVOR NXHwdmhScW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6 MVWyOVAxQTJ7NR?=
OCI-Ly8 NILNXJVCeG:ydH;zbZMhSXO|YYm= MVOxO|IwOjVyIH7N NWTXb4g4P2R? M3jpe2ROW09? MVTpcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= NVLEPXZEOjVyMEmyPVU>
SU-DHL-4 NV3BbJJoSXCxcITvd4l{KEG|c3H5 NF70UXcyPzJxMkWwJI5O MmnMO4Q> M4HtemROW09? Mk\1bY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 MVWyOVAxQTJ7NR?=
SU-DHL-10 Ml\zRZBweHSxc3nzJGF{e2G7 MnznNVczNzJ3MDDuUS=> Mnq0O4Q> NIrUNIVFVVOR NH7tN|FqdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> NELYSngzPTByOUK5OS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pDNA-PKcs / γH2AX / Ub-γH2AX / p-c-Jun S63 / Bax; 

PubMed: 26119999     


The comparative effects of the active (+)-JQ1 vs. the inactive (−)-JQ1 on the cellular responsiveness to radiation and the cell fate decision. 

c-Myc; 

PubMed: 23792448     


PEL and non-PEL (Namalwa) cells treated with indicated doses of (+)-JQ1 for 48 hours were lysed and analyzed by Western blot for the expression of c-Myc. GAPDH was used as a loading control. 

p27; 

PubMed: 23792448     


Western blot analysis showing induction of p27 upon 48 hours of treatment with (+)-JQ1. GAPDH serves as a loading control.

26119999 23792448
Growth inhibition assay
Cell viability; 

PubMed: 23792448     


PEL cell lines (BC1, BC3, BCBL1 and JSC1) were treated with indicated doses of (-)-JQ1 or (+)-JQ1 for 5 days and cell viability measured using an MTS assay (refer to Materials and methods). Namalwa, a Burkitt's lymphoma cell line, was used as a control. 

23792448
Immunofluorescence
GM130; 

PubMed: 29074567     


Representative images of A549cells treated with single compounds or in combination (as indicated) are shown. 

MHC / EdU; 

PubMed: 28733670     


C2C12 cultures were switched to DM and treated with 1 µM (+)-JQ1, (−)-JQ1, DMSO or untreated (DM only). Cells were fixed at 12, 24, 48 and 72 hours after treatment and pulsed with EdU 2 hours before fixation. EdU positive nuclei were stained with Alexa Fluor 555 and cultures immunostained for MHC.

29074567 28733670
In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID